Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma
Advances in Medical Sciences · 2025
DOI: 10.1016/j.advms.2025.01.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Medical Sciences, 2025. Verfasst von Jiaxin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Second Clinical Medical College of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Autoantibodies, Liver Neoplasms, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: In this study, we examined novel autoantibodies targeting tumor-associated antigens (TAAs) as biomarkers for clinical assessment of hepatocellular carcinoma (HCC) in a Chinese population. METHODS AND METHODS: A total of 119 patients with HCC and 130 healthy control (HC) volunteers who were age and gender matched were enrolled. The levels of circulating IgG antibodies were detected using an enzyme-linked immunosorbent test (ELISA) developed in-house with linear peptide antigens derived from Annexin A1(ANXA1) and proto-oncogene protein (MYC). The significant level was set at P 0.025). There was a significant increase in these two plasma IgG autoantibodies in male HCC patients (ANXA1: t = -3.590, P < 0.001; MYC: t = -2.706, P = 0.007). Pearson correlation analysis demonstrated that both anti-ANXA1 and anti-MYC IgG levels had a positive correlation with BCLC staging (both P < 0.025) but a negative correlation with plasma albumin (Alb) (both P < 0.025). The area under the ROC curve (AUC) values were 0.613 for anti-ANXA1 IgG assay and 0.567 for anti-MYC IgG assay. The anti-ANAXA1 IgG assay showed a high sensitivity of 31.4 % against the specificity of 90.0 % for detection of BCLC stages C + D. CONCLUSIONS: Plasma anti-ANXA1 and anti-MYC autoantibodies are likely to serve as a potential biomarker for clinical assessment of HCC prognosis, particularly in male patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The Second Clinical Medical College of Jilin University, Changchun, China.
- Department of Hepatopancreatobiliary Medicine, The Second Clinical Medical College of Jilin University, Changchun, China.
- Department of Science and Technology, The Second Clinical Medical College of Jilin University, Changchun, China. Electronic address: zhangxuankj@163.com.
Zitieren
APA
Wang, J., Liu, S., & Zhang, X. (2025). Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma. Advances in Medical Sciences. https://doi.org/10.1016/j.advms.2025.01.004
Vancouver
Wang J, Liu S, Zhang X. Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma. Advances in Medical Sciences. 2025. doi:10.1016/j.advms.2025.01.004
BibTeX
@article{Wang2025,
author = {Wang, Jiaxin and Liu, Siqi and Zhang, Xuan},
title = {Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma},
journal = {Advances in Medical Sciences},
year = {2025},
doi = {10.1016/j.advms.2025.01.004}
}
EUVIMED